BiotechTube

Nivolumab + Cetuximab

Phase 1/2Completed
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Squamous Cell Carcinoma of the Oropharynx

Conditions

Squamous Cell Carcinoma of the Oropharynx, Squamous Cell Carcinoma of the Larynx, Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Hypopharynx, Squamous Cell Carcinoma of the Paranasal Sinus, Head and Neck Squamous Cell Carcinoma, Squamous Cell Cancer, Head and Neck Carcinoma

Trial Timeline

Dec 20, 2017 → Dec 23, 2023

NCT ID
NCT03370276

About Nivolumab + Cetuximab

Nivolumab + Cetuximab is a phase 1/2 stage product being developed by Eli Lilly for Squamous Cell Carcinoma of the Oropharynx. The current trial status is completed. This product is registered under clinical trial identifier NCT03370276. Target conditions include Squamous Cell Carcinoma of the Oropharynx, Squamous Cell Carcinoma of the Larynx, Squamous Cell Carcinoma of the Oral Cavity.

What happened to similar drugs?

4 of 20 similar drugs in Squamous Cell Carcinoma of the Oropharynx were approved

Approved (4) Terminated (2) Active (14)
✅Pembrolizumab + Carboplatin + PaclitaxelMerckApproved
✅erlotinib [Tarceva]RocheApproved
✅erlotinib [Tarceva]RocheApproved
✅Platinum-based chemotherapy + Bevacizumab [Avastin]RocheApproved
🔄CT-P51 + EU-approved KeytrudaCelltrionPhase 3
🔄Ifinatamab deruxtecan + Docetaxel + Paclitaxel + Irinotecan hydrochloride (HCl)Daiichi SankyoPhase 3
🔄Patritumab Deruxtecan + Platinum-based chemotherapyDaiichi SankyoPhase 3

Hype Score Breakdown

Clinical
9
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03370276Phase 1/2Completed

Competing Products

20 competing products in Squamous Cell Carcinoma of the Oropharynx

See all competitors
ProductCompanyStageHype Score
AFM24 + SNK01AffimedPhase 1/2
14
Sintilimab + Nab paclitaxel + CisplatinCSPC Pharmaceutical Group LimitedPhase 2
35
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
27
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
35
Cemiplimab + CetuximabEli LillyPhase 2
42
Necitumumab-Gemcitabine-CisplatinEli LillyPhase 2
27
BB-401Benitec BiopharmaPhase 2
25
Ramucirumab + PaclitaxelEli LillyPhase 2
35
Gemcitabine + ACR-368Acrivon TherapeuticsPhase 2
32
CT-P51 + EU-approved KeytrudaCelltrionPhase 3
47
Pembrolizumab + I-DXd + Leucovorin + Levoleucovorin + 5-Fluorouracil (5-FU) + Oxaliplatin + Sacituzumab tirumotecan + Rescue MedicationDaiichi SankyoPhase 1/2
39
Ifinatamab deruxtecan + Docetaxel + Paclitaxel + Irinotecan hydrochloride (HCl)Daiichi SankyoPhase 3
47
I-DXd + Rescue MedicationDaiichi SankyoPhase 1/2
39
Patritumab + Cetuximab + Cisplatin + CarboplatinDaiichi SankyoPhase 1
29
Patritumab Deruxtecan + Platinum-based chemotherapyDaiichi SankyoPhase 3
44
Tivantinib + Placebo + ErlotinibDaiichi SankyoPhase 3
32
Avelumab + enfortumab vedotinAstellas PharmaPhase 2
42
Enfortumab Vedotin + PembrolizumabAstellas PharmaPhase 2
42
avelumab + Bempegaldesleukin + talazoparib + enzalutamideAstellas PharmaPhase 1/2
24
Drug Combination TherapySun PharmaceuticalPhase 2
42